Addpharma, a subsidiary of Yuhan's improved drug development, has entered phase 3 clinical trials of low-dose tablets of Dutasteride (Avodart, GSK), a hair loss treatment.

Currently, Dutasteride is already on the market, but the value of Addpharma's developed products is high as there is no low dose product.

The MFDS approved Addpharma's phase 3 clinical trial protocol for AD-208 on the 29th of last month. This trial is a multicenter, randomized, double-blind, placebo-controlled, parallel, phase 3 clinical trial to evaluate the efficacy and safety of AD-208 in male androgen alopecia patients.

AD-208 is Yuhan's IMD. However, it is not known in detail what type of dru